Compare FDS & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDS | TWST |
|---|---|---|
| Founded | 1978 | 2013 |
| Country | United States | United States |
| Employees | 6258 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 9.2B |
| IPO Year | 1996 | 2018 |
| Metric | FDS | TWST |
|---|---|---|
| Price | $328.76 | $152.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 13 |
| Target Price | ★ $280.63 | $168.25 |
| AVG Volume (30 Days) | 635.1K | ★ 2.8M |
| Earning Date | 12-17-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 14.57 | N/A |
| Revenue | ★ $1,435,351,000.00 | $376,572,000.00 |
| Revenue This Year | $5.79 | $21.17 |
| Revenue Next Year | $5.96 | $20.24 |
| P/E Ratio | $21.88 | ★ N/A |
| Revenue Growth | 6.31 | ★ 20.32 |
| 52 Week Low | $185.00 | $23.30 |
| 52 Week High | $339.83 | $219.71 |
| Indicator | FDS | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 64.90 | 49.20 |
| Support Level | $195.87 | $122.05 |
| Resistance Level | $339.83 | $155.44 |
| Average True Range (ATR) | 10.70 | 13.90 |
| MACD | 1.68 | 1.25 |
| Stochastic Oscillator | 79.70 | 45.60 |
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.